If you are not happy with the results below please do another search
Post hoc analyses found a statistically significant reduction in the duration of flu infection and a dose-related trend toward a reduction in symptom duration. These results support the further clinical development of INNA-051 to mitigate the impact of natural infection by respiratory viruses such as SARS-CoV-2 and its variants: influenza, RSV, and the common cold, […]
Sydney, Australia – ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pan-antiviral prophylaxis in at-risk populations and pandemic preparedness, has been selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation – JLABS (JLABS) and the Biomedical Advanced Research and Development Authority (BARDA), a component […]
ENA Respiratory begins influenza challenge study for fast-acting nasal spray INNA-051, designed to boost innate immunity in patients at high risk of severe complications from respiratory infections Sydney, Australia, 15th March 2022 – ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum antiviral innate immunomodulator for pre- and post-exposure prophylaxis of respiratory viral […]
INNA-051 is being developed to stimulate innate immunity and reduce the incidence and severity of respiratory viral infections, such as COVID-19, rhinovirus, or influenza in populations at-risk of complications that include individuals with COPD Sydney, Australia, and Miami, Florida. – 23 February 2022 – ENA Respiratory, a clinical-stage pharmaceutical company developing INNA-051, a first-in-class broad-spectrum […]
Research on preventative nasal spray, which protects against COVID-19 and common cold, published in leading peer-reviewed academic journals Research on preventative COVID-19 nasal spray published in prestigious, peer-reviewed academic journals: EBioMedicine and the European Respiratory Journal Novel therapy developed by Australian biotech company, Ena Respiratory, shown in animal study to reduce COVID-19 virus levels in […]
ENA Respiratory engages PPD, Inc. for Phase 2 COVID-19 post-exposure prophylaxis study and hVIVO for influenza challenge study to assess the efficacy of fast-acting nasal spray designed to boost innate immunity Sydney, Australia, 28 September 2021 – ENA Respiratory, a biotechnology company developing a first-in-class nasal spray for the prevention of COVID-19 and other respiratory […]
First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal for most infections Company is recruiting study participants in the Sydney, Australia area Sydney, Australia, 13 July 2021 – ENA Respiratory, a biotechnology company developing a first-in-class nasal […]
When compared to placebo, prophylactic administration of INNA-051 was associated with significantly increased expression of multiple host defense genes and shorter duration of infection in influenza virus-infected individuals Data published in ERJ Open Research, a leading open access journal in respiratory medicine Melbourne, Australia, 18 December 2024 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
New intranasal formulation with significantly improved stability was well-tolerated and led to local activation of innate immune pathways in adults aged >60 S. Department of Defense (DOD) funded study extension into younger adults aged 18 – 45 will complete dosing in January Melbourne, Australia, 22 January 2025 – ENA Respiratory, a clinical-stage pharmaceutical company developing […]
INNA-051 increased early expression of multiple antiviral effector genes compared with placebo and shortened viral shedding duration in participants with confirmed influenza infection Melbourne, Australia and Milan, Italy, 11 September 2023 – ENA Respiratory, a clinical-stage pharmaceutical company, announced positive data from the Phase 2a flu challenge study of INNA-051, a first-in-class, broad-spectrum, innate immunomodulator […]
